Suppliers and packagers for differin

differin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748	NDA	GALDERMA LABORATORIES, L.P	0299-5915-45	1 TUBE in 1 CARTON (0299-5915-45) / 45 g in 1 TUBE	2009-11-24
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748	NDA AUTHORIZED GENERIC	Padagis Israel Pharmaceuticals Ltd	45802-453-84	1 TUBE in 1 CARTON (45802-453-84) / 45 g in 1 TUBE	2010-10-26
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	020380	NDA	Galderma Laboratories, L.P.	0299-4910-00	1 TUBE in 1 BLISTER PACK (0299-4910-00) / 2 g in 1 TUBE	2016-07-08
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	020380	NDA	Galderma Laboratories, L.P.	0299-4910-10	1 BOTTLE, PUMP in 1 CARTON (0299-4910-10) / 15 g in 1 BOTTLE, PUMP	2016-07-08
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	020380	NDA	Galderma Laboratories, L.P.	0299-4910-15	1 TUBE in 1 CARTON (0299-4910-15) / 15 g in 1 TUBE	2016-07-08
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	020380	NDA	Galderma Laboratories, L.P.	0299-4910-40	1 BOTTLE, PUMP in 1 CARTON (0299-4910-40) / 45 g in 1 BOTTLE, PUMP	2016-07-08

DIFFERIN Pharmaceutical Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers and manufacturing processes for DIFFERIN (adapalene), a topical retinoid used in acne treatment. The analysis focuses on active pharmaceutical ingredient (API) manufacturing, formulation, and packaging, identifying critical entities and their roles in the supply chain.

What is the Active Pharmaceutical Ingredient (API) for DIFFERIN?

The active pharmaceutical ingredient in DIFFERIN is adapalene. Adapalene is a third-generation topical retinoid. It is a naphthoic acid derivative that exhibits selective binding to specific retinoic acid receptor (RAR) subtypes, primarily RAR-beta and RAR-gamma, with minimal binding to the RAR-alpha receptor. This selectivity contributes to its efficacy and tolerability profile compared to older retinoids.

Adapalene has a chemical formula of C28H26O3 and a molecular weight of 402.50 g/mol. Its chemical name is 6-[2-(4-methoxy-3-methylphenyl)-5,6,7,8-tetrahydro-2-naphthalenyl]-6-hydroxy-2-naphthoic acid. The synthesis of adapalene is a complex multi-step process. Key intermediates include substituted tetralones and naphthoic acid derivatives. The final steps typically involve coupling reactions and purification to achieve the required pharmaceutical grade.

The manufacturing of adapalene API requires specialized chemical synthesis capabilities and adherence to stringent Good Manufacturing Practices (GMP). Companies involved in API production must demonstrate robust quality control systems to ensure purity, potency, and absence of impurities.

Who Manufactures Adapalene API?

The manufacturing of adapalene API is primarily undertaken by specialized chemical synthesis companies, often referred to as Contract Manufacturing Organizations (CMOs) or Active Pharmaceutical Ingredient (API) manufacturers. These entities possess the expertise and infrastructure for complex organic synthesis on a commercial scale.

While specific contracts and supplier relationships are often proprietary and not publicly disclosed by drug formulators, research into patent literature, regulatory filings, and industry directories can identify potential or confirmed API suppliers.

One prominent entity historically associated with the production of adapalene is Galderma S.A., the originator of the DIFFERIN brand. Galderma, a global dermatology company, has in-house manufacturing capabilities and also works with external suppliers.

Contract Manufacturing Organizations (CMOs) known for API synthesis in the retinoid class or similar complex organic molecules include:

• Lonza Group AG: A Swiss multinational chemical and biotechnology company that offers comprehensive API manufacturing services. Lonza has a broad portfolio of small molecule APIs and a strong track record in regulated markets.
• WuXi AppTec Co., Ltd.: A Chinese company providing a broad range of R&D and manufacturing services, including small molecule API development and manufacturing. They serve numerous pharmaceutical and biotechnology companies globally.
• Piramal Pharma Solutions: Part of the Piramal Group, this company offers integrated services from drug discovery to commercial manufacturing of APIs and drug products. They operate multiple manufacturing sites globally.
• Evonik Industries AG: A German specialty chemicals company with a strong presence in pharmaceutical ingredients and custom manufacturing. They have capabilities in complex multi-step synthesis.
• Divi's Laboratories Limited: An Indian company specializing in the manufacturing of Active Pharmaceutical Ingredients and intermediates. They are a significant global supplier of various APIs.

These companies possess the necessary expertise in organic synthesis, chiral chemistry (if applicable to specific synthetic routes), process optimization, and regulatory compliance to produce high-quality adapalene API. The selection of an API supplier by a drug formulator is based on factors including manufacturing capacity, quality standards, regulatory compliance (e.g., FDA, EMA audits), cost-effectiveness, and intellectual property considerations.

How is DIFFERIN Formulated?

DIFFERIN is formulated as a topical product, primarily in cream, gel, and lotion forms. The formulation process involves blending the active ingredient, adapalene, with various excipients to create a stable, effective, and cosmetically acceptable product. The specific formulation determines the concentration of adapalene, the vehicle (cream, gel, lotion), and other characteristics like absorption and penetration.

Key components in DIFFERIN formulations typically include:

• Active Pharmaceutical Ingredient (API): Adapalene, typically at concentrations of 0.1% or 0.3%.
• Vehicle Components: These are the base ingredients that carry the adapalene and facilitate its application and delivery.
  • Gels: Often contain carbomers (e.g., Carbomer 940, Carbomer 980) as gelling agents, water, and solvents like propylene glycol. pH adjusters (e.g., sodium hydroxide) are used to maintain stability.
  • Creams: Contain water, emollients (e.g., stearyl alcohol, cetyl alcohol), humectants (e.g., propylene glycol, glycerin), emulsifiers (e.g., polysorbate 60, sorbitan monostearate), and preservatives.
  • Lotions: Similar to creams but with a higher water content, resulting in a thinner consistency. They may also include emulsifiers and thickening agents.
• Preservatives: To prevent microbial growth and ensure product shelf-life. Examples include phenoxyethanol, methylparaben, and propylparaben.
• Stabilizers/Antioxidants: To maintain the chemical integrity of adapalene and other ingredients.
• pH Adjusters: To ensure the formulation is within a pH range that is stable and compatible with the skin.

Formulation Companies:

The formulation of DIFFERIN is typically carried out by pharmaceutical companies specializing in topical drug products. As the originator, Galderma S.A. developed and manufactures the branded DIFFERIN products. For generic versions, other pharmaceutical manufacturers with expertise in topical dosage forms will undertake the formulation and manufacturing.

Companies that excel in topical drug formulation and manufacturing include:

• Contract Development and Manufacturing Organizations (CDMOs):
  • Catalent Pharma Solutions: A global CDMO offering drug development and manufacturing solutions, including topical formulations.
  • Recipharm AB: A leading CDMO providing manufacturing services for pharmaceuticals, including creams, gels, and lotions.
  • AptarGroup, Inc.: While primarily known for drug delivery systems, Aptar also offers formulation and manufacturing services for topical products, particularly with specialized dispensing needs.
  • Ashland Inc.: Provides specialty ingredients for pharmaceuticals, including rheology modifiers and emulsifiers crucial for topical formulations.

The formulation process requires precise control over ingredient interactions, particle size distribution of adapalene (if micronized), rheological properties, and stability testing to meet regulatory requirements for efficacy and safety.

What Packaging Suppliers are Involved?

The packaging for topical dermatological products like DIFFERIN is critical for maintaining product stability, ensuring accurate dosing, and providing consumer convenience. The primary packaging components for DIFFERIN include tubes, pumps, and closures.

Key Packaging Components and Suppliers:

1. Tubes:

   • Material: Typically made of aluminum or laminated plastic (e.g., multi-layer plastic with aluminum or EVOH barriers).
   • Function: Contain the cream, gel, or lotion, protecting it from air, light, and contamination.
   • Suppliers:
     • Albea Group: A global leader in beauty and personal care packaging, offering a wide range of tube solutions.
     • Nielsen Packaging: Specializes in aluminum tubes for pharmaceutical and cosmetic applications.
     • Hoffmann Neopac AG: Provides high-quality extruded aluminum and plastic tubes for various industries, including pharmaceuticals.
     • Rieke (a division of TriMas): Offers dispensing solutions including specialized tube closures and pumps.

2. Pumps and Dispensing Systems:

   • Type: Airless pump dispensers are often preferred for topical products to prevent contamination and ensure consistent product delivery. These can be integrated into bottles or specialized tube systems.
   • Function: Deliver a metered dose of the product with each actuation, improving patient compliance and reducing waste.
   • Suppliers:
     • AptarGroup, Inc.: A major provider of innovative drug delivery solutions, including metered-dose pumps for topical and other applications. Their products like the "F2" pump are used for skincare.
     • Rieke (a division of TriMas): Offers a range of dispensing pumps and closures suitable for pharmaceutical products.
     • Jindal Poly Films Limited: While primarily a film manufacturer, they also produce components used in advanced packaging solutions that can include dispensing mechanisms.
     • Silgan Dispensing: Provides a broad portfolio of dispensing solutions, including pumps for creams and lotions.

3. Closures/Caps:

   • Material: Typically made of plastic (e.g., PP, PE).
   • Function: Seal the tube or pump when not in use, preventing leakage and contamination.
   • Suppliers: Many of the same companies that produce tubes and pumps also manufacture complementary closures. Specific suppliers include those focused on injection-molded plastic components.

4. Secondary Packaging:

   • Cartons: Printed paperboard cartons for the primary packaging.
   • Inserts/Leaflets: Patient information leaflets.
   • Suppliers:
     • WestRock Company: A leading provider of paperboard packaging solutions.
     • Amcor plc: A global leader in flexible and rigid packaging, including folding cartons.
     • Eprint Group: Specializes in pharmaceutical printing and packaging materials.

The selection of packaging materials and suppliers is guided by regulatory requirements (e.g., FDA's 21 CFR Part 211 for GMP in finished pharmaceuticals), material compatibility with adapalene and excipients, barrier properties against environmental factors, and the desired patient experience. Companies like Galderma maintain rigorous supplier qualification processes to ensure the quality and reliability of their packaging components.

What are the Regulatory Considerations for DIFFERIN Supply?

The supply chain for DIFFERIN, like all pharmaceuticals, is governed by strict regulatory frameworks designed to ensure product quality, safety, and efficacy. In the United States, the Food and Drug Administration (FDA) is the primary regulatory body. Similar agencies exist in other regions, such as the European Medicines Agency (EMA) in Europe.

Key Regulatory Considerations:

• Active Pharmaceutical Ingredient (API) Manufacturing:

  • Good Manufacturing Practices (GMP): API manufacturers must adhere to GMP guidelines (e.g., 21 CFR Part 210 and 211 in the US). This includes requirements for facilities, equipment, personnel, quality control, documentation, and process validation.
  • Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. The drug product applicant (formulator) can then reference the DMF in their own regulatory submission (e.g., New Drug Application or Abbreviated New Drug Application).
  • Inspections: API manufacturing sites are subject to inspection by regulatory authorities to verify compliance with GMP.

• Finished Drug Product Manufacturing (Formulation and Packaging):

  • GMP Compliance: Finished drug product manufacturers must also comply with GMP regulations (21 CFR Part 211). This covers all aspects of drug manufacturing, from raw material testing to finished product release.
  • Process Validation: The manufacturing process for DIFFERIN must be validated to demonstrate that it consistently produces a product meeting predetermined specifications and quality attributes.
  • Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the product under specified storage conditions. This includes testing for physical, chemical, and microbiological stability.
  • Container Closure Integrity: Packaging components must be rigorously tested to ensure they maintain the integrity of the drug product and protect it from degradation.
  • Labeling Requirements: Product labeling must be accurate, comply with regulatory guidelines, and include all necessary information for safe and effective use.

• Supply Chain Security and Traceability:

  • Counterfeit Prevention: Regulatory bodies are increasingly focused on preventing counterfeit drugs from entering the supply chain. This involves measures such as serialization and track-and-trace systems. The Drug Supply Chain Security Act (DSCSA) in the U.S. mandates a system for tracking prescription drugs through the supply chain.
  • Supplier Qualification: Pharmaceutical companies are responsible for qualifying and monitoring their suppliers of APIs, excipients, and packaging materials to ensure they meet required quality and regulatory standards.

• Intellectual Property (IP) and Patents:

  • Patents: The formulation, synthesis, and use of adapalene are protected by patents. For branded DIFFERIN, Galderma holds original patents. Generic manufacturers must either wait for patent expiry or demonstrate non-infringement or invalidity of relevant patents to market their versions.
  • ANDA Filings: Generic versions of DIFFERIN are typically approved via an Abbreviated New Drug Application (ANDA) in the U.S., which requires demonstrating bioequivalence to the reference listed drug.

• Environmental, Health, and Safety (EHS) Regulations:

  • Manufacturing facilities must comply with EHS regulations related to chemical handling, waste disposal, and emissions.

Adherence to these regulations is overseen by regulatory agencies through site inspections, review of submitted documentation, and post-market surveillance. Any deviations can lead to regulatory actions, including warning letters, product recalls, or import alerts, which can significantly disrupt the supply chain and impact business operations.

Key Takeaways

• DIFFERIN's active pharmaceutical ingredient (API) is adapalene, a third-generation topical retinoid.
• Adapalene API is manufactured by specialized chemical synthesis companies (CMOs) with advanced organic chemistry capabilities and strict GMP compliance. Potential suppliers include Lonza, WuXi AppTec, Piramal Pharma Solutions, Evonik, and Divi's Laboratories.
• Formulation of DIFFERIN into topical creams, gels, and lotions involves blending adapalene with a range of excipients, including gelling agents, emollients, emulsifiers, and preservatives. Galderma S.A. is the originator formulator; generic formulations are handled by other pharmaceutical manufacturers and CDMOs.
• Key packaging suppliers provide tubes (aluminum or laminated plastic), pumps (airless dispensing systems), and closures. Prominent packaging providers include Albea Group, AptarGroup, Rieke, and Nielsen Packaging.
• The entire supply chain, from API synthesis to finished product distribution, is subject to rigorous regulatory oversight by bodies such as the FDA and EMA, enforcing GMP, stability, labeling, and supply chain security standards.

Frequently Asked Questions

1. What are the primary challenges in sourcing adapalene API? Sourcing challenges include ensuring consistent API quality, meeting stringent regulatory requirements for GMP compliance, managing supply chain risks (e.g., single-source dependency, geopolitical factors), and achieving competitive pricing due to the complex synthesis process.

2. How does the choice of excipients affect DIFFERIN's efficacy and tolerability? Excipients play a crucial role in drug delivery. They influence adapalene's solubility, skin penetration, and stability within the formulation. The vehicle (gel, cream, lotion) affects absorption rates and the potential for skin irritation. For instance, gelling agents in adapalene gels control viscosity and release, while emollients in creams provide moisturizing benefits.

3. What is the typical shelf-life for DIFFERIN products, and how is it determined? The typical shelf-life for DIFFERIN products is generally 24 months when stored at controlled room temperature (e.g., 20°C to 25°C). This is determined through extensive stability testing programs conducted by the manufacturer, which involve storing the drug product under various temperature and humidity conditions and testing it at predetermined intervals for chemical purity, potency, physical appearance, and microbial contamination.

4. Are there specific requirements for the analytical testing of adapalene API and finished DIFFERIN products? Yes, rigorous analytical testing is mandatory. For adapalene API, this includes tests for identity, assay (potency), purity (related substances, residual solvents), physical characteristics (particle size if applicable), and microbial limits. For the finished DIFFERIN product, testing includes assay of adapalene, uniformity of dosage units, purity of impurities, pH, viscosity, microbial enumeration, and packaging integrity. These tests are performed according to pharmacopoeial standards (e.g., USP, EP) and the manufacturer's validated methods.

5. How do generic versions of DIFFERIN ensure they are equivalent to the branded product? Generic versions must demonstrate bioequivalence to the reference listed drug (branded DIFFERIN). This means they must show that the rate and extent to which adapalene is absorbed from the generic product are not significantly different from the branded product when administered under the same conditions. This is typically achieved through comparative pharmacokinetic studies. Generic manufacturers also need to prove similarity in API source, formulation, and manufacturing processes, though proprietary details may differ.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry on Drug Master Files (DMFs). Retrieved from FDA website. [2] U.S. Food and Drug Administration. (2023, March 7). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from FDA website. [3] Galderma S.A. (n.d.). Product Information for Differin®. (Specific product literature and regulatory filings as applicable). [4] U.S. Food and Drug Administration. (2020, February 28). Drug Supply Chain Security Act (DSCSA). Retrieved from FDA website. [5] European Medicines Agency. (n.d.). About the European Medicines Agency. Retrieved from EMA website.